Zobrazeno 1 - 2
of 2
pro vyhledávání: '"35"'
Autor:
Koichi Goto, Mitsuhiro Takenoyama, Koji Takeda, Shinji Atagi, Hidehito Horinouchi, M. Nishio, Tomohide Tamura, Naoyuki Nogami, Kazuhiko Nakagawa, Tomonori Hirashima, Hideo Saka, Naoki Sumiyoshi, Hiroshi Isobe, Hiroshi Sakai, Miyako Satouchi, Toyoaki Hida, Toshiaki Takahashi, Hiroshi Tanaka, Koichi Minato, Makoto Maemondo, Nobuyuki Katakami
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 8, Iss 11, Pp 5183-5193 (2019)
Cancer Medicine, Vol 8, Iss 11, Pp 5183-5193 (2019)
Background Nivolumab is a programmed cell death 1 (PD‐1) receptor inhibitor antibody that enhances immune system antitumor activity. It is associated with longer overall survival (OS) than the standard treatment of docetaxel in patients with previo
Autor:
Shintaro Iwama, Yutaka Fujiwara, Aya Kuchiba, Noboru Yamamoto, Naoya Yamazaki, Yuichiro Ohe, Shiro Kimbara, Ken Ohashi, Shigehisa Kitano, Hiroshi Arima
Publikováno v:
Cancer Science
Thyroid dysfunction (TD) induced by immune checkpoint inhibitors is not sufficiently understood. The purpose of this retrospective observational study was to identify risk factors and the clinical course of TD induced by nivolumab. Patients with adva